Journal
BRITISH JOURNAL OF CANCER
Volume 100, Issue 10, Pages 1627-1637Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.bjc.6605029
Keywords
neuroblastoma; INRG; minimal disease; immunocytology; QRT-PCR
Categories
Funding
- William Guy Forbeck Research Foundation
Ask authors/readers for more resources
Disseminating disease is a predictive and prognostic indicator of poor outcome in children with neuroblastoma. Its accurate and sensitive assessment can facilitate optimal treatment decisions. The International Neuroblastoma Risk Group (INRG) Task Force has defined standardised methods for the determination of minimal disease (MD) by immunocytology (IC) and quantitative reverse transcriptase-polymerase chain reaction (QRT-PCR) using disialoganglioside G(D2) and tyrosine hydroxylase mRNA respectively. The INRG standard operating procedures (SOPs) define methods for collecting, processing and evaluating bone marrow (BM), peripheral blood (PB) and peripheral blood stem cell harvest by IC and QRT-PCR. Sampling PB and BM is recommended at diagnosis, before and after myeloablative therapy and at the end of treatment. Peripheral blood stem cell products should be analysed at the time of harvest. Performing MD detection according to INRG SOPs will enable laboratories throughout the world to compare their results and thus facilitate quality-controlled multi-centre prospective trials to assess the clinical significance of MD and minimal residual disease in heterogeneous patient groups. British Journal of Cancer (2009) 100, 1627-1637. doi: 10.1038/sj.bjc.6605029 www.bjcancer.com Published online 28 April 2009 (C) 2009 Cancer Research UK
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available